USPTO serial 90298508
BORA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 21, 2023
- Examiner
- FRIEDMAN, LESLEE ANN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BORA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
BORA PHARMACEUTICALS CO., LTD.
Taipei City, TW
BORA PHARMACEUTICALS CO., LTD.
Taipei City, TW
BORA PHARMACEUTICALS CO., LTD.
Taipei City, TW
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Hui Zhang
Hui Zhang RABIN & BERDO, P.C.2650 PARK TOWER DRIVE, SUITE 800VIENNA, VA 22180UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Nutritional supplements; Antiallergic medicines; Sulphonamides as medicines; Medicines for intestinal disorders; Medicines for dental purposes; Medicines for alleviating constipation; Motion sickness medicines; Medicines for the treatment of gastrointestinal diseases; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Ocular pharmaceuticals; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Anti-diabetic pharmaceuticals; Pharmaceuticals, namely, psychotropics; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, inducers of erections; Injectable pharmaceuticals for treatment of anaphylactic reactions; Pharmaceuticals, namely, lipid lowering agents; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Astringents for medicinal purposes; Pharmaceutical preparations for wounds; Dermatological pharmaceutical products; Pharmaceutical skin lotions; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for skin care; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations for use in urology; Pharmaceutical products and preparations for chloasma; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating diabetes; Pharmaceutical solutions used in dialysis; Pharmaceutical products for ophthalmological use; Anti-epileptic pharmaceutical preparations; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating hypertension; Pharmaceutical antitussive-cold preparations; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating halitosis; Effervescent analgesic pharmaceutical preparations; Pharmaceutical products for the prevention and treatment of cancer; Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting sensory organs; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products for the treatment of joint disease; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the relief of insect bites; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for treating allergic rhinitis; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BORA PHARMACEUTICALS CO., LTD.
- Other trademarks owned by BORA PHARMACEUTICALS CO., LTD.
- Other trademarks owned by BORA PHARMACEUTICALS CO., LTD.
- Other trademarks in Class 005
- Similar marks named BORA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 21, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 21, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 3, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 3, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 14, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 30, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 9, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 9, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 8, 2022 | ALIE | ASSIGNED TO LIE | — |
| Nov 1, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| May 16, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 16, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 16, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 16, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| May 12, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 12, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 12, 2022 | ALIE | ASSIGNED TO LIE | — |
| May 10, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Dec 11, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Dec 11, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Dec 11, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 22, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 20, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 20, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 20, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 29, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 28, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 28, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 10, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 10, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 10, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 9, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 4, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 7, 2020 | NWAP | NEW APPLICATION ENTERED | — |